MGH has been at the forefront of many scientific advances in treatments for depression.
Dr. George I. Papakostas is scientific director of the MGH Clinical Trials Network and Institute, director of treatment-resistant depression studies in the department of psychiatry at MGH, and associate professor of psychiatry at Harvard Medical School. He is also director of a Harvard-wide course on the design and conduct of clinical trials in medicine. Dr. Papakostas is field editor for psychopharmacology for the World Journal of Biological Psychiatry and on the editorial board of The Journal of Clinical Psychiatry, and Psychiatry Research. The focus of Dr. Papakostas’ research includes the pharmacotherapy of major depressive disorder, including treatment-resistant depression; the study of the placebo effect and its relevance to clinical trial design in mood and anxiety disorders; and the study of clinical and biologic predictors, moderators, and mediators of treatment outcome in major depressive disorder. Dr. Papakostas is co-principal investigator of the RAPID Network, the NIMH-funded series of studies of novel, rapidly acting antidepressant therapies. Dr. Papakostas has received numerous national and international research awards, including from the American College of Neuropsychopharmacology, the Collegium Internationale Neuropsychopharmacologium, the New Clinical Drug Evaluation Unit of the National Institute of Mental Health, the American Psychiatric Association, the World Federation of Societies of Biological Psychiatry, the American Academy of Clinical Psychiatrists, the International College of Psychosomatic Medicine, and the American Foundation for Suicide Prevention. View Dr. Papakostas’ research: http://www.ncbi.nlm.nih.gov/pubmed/?term=Papakostas+GI+%5BAuthor%5D